Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-033: sacituzumab tirumotecan + pembrolizumab vs pembrolizumab for pMMR endometrial carcinoma maintenance
2024-519331-42-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Sacituzumab tirumotecan + pembrolizumab maintenance with Pembrolizumab monotherapy maintenance (2 arms). Primary endpoints: Progression Free Survival (PFS) during maintenance treatment and Overall Survival (OS) during maintenance treatment. Planned start Jun 2025; status: authorised.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-519331-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519331-42-00.